Non-Hodgkin Lymphoma | Specialty

Follicular Lymphoma: Optimizing Copanlisib

October 21st 2017

Follicular Lymphoma: Defining Copanlisib

October 21st 2017

Follicular Lymphoma: Overview of Treatment Options

October 21st 2017

Follicular Lymphoma: Outcomes with Immunotherapy

October 21st 2017

FDA Approves Axicabtagene Ciloleucel for Non-Hodgkin Lymphoma

October 19th 2017

The FDA has approved the CD19-directed CAR T-cell therapy axicabtagene ciloleucel as a treatment for adults with relapsed or refractory non-Hodgkin lymphoma.

Dr. Karmali on FDA Approval of KTE-C19 in Non-Hodgkin Lymphoma

October 19th 2017

Reem Karmali, MD, assistant professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern University, discusses the FDA approval of axicabtagene ciloleucel (KTE-C19; axi-cel) for the treatment of patients with non-Hodgkin lymphoma.

Expert Covers Burgeoning Advancements in Follicular Lymphoma and MCL

October 18th 2017

Narendranath Epperla, MD, discusses the evolving treatment landscape for patients with follicular lymphoma and mantle cell lymphoma.

Copanlisib Induces Nearly 1-Year Median PFS in Heavily Pretreated Indolent Lymphoma

October 11th 2017

Treatment with copanlisib led to a median progression-free survival of 11.2 months and objective response rate of 59.2% in patients with relapsed/refractory indolent lymphoma.

Dr. Winter on the Promise of CAR T-Cell Therapy in Hematologic Malignancies

October 11th 2017

Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses the promise of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies.

TP53 Predicts Poorer Survival in Mantle Cell Lymphoma

October 9th 2017

Multivariate analysis of the Nordic MCL2 and MCL3 trials showed that the presence of TP53 mutations predicted worse overall survival in younger patients with mantle cell lymphoma.

Dr. Winter Discusses Response in Follicular Lymphoma

October 8th 2017

Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses response in follicular lymphoma.

Data Emerges on Maintenance Therapies, Developing Treatments for Relapsed/Refractory FL

October 8th 2017

Survival for patients with grade 1 to 2 follicular lymphoma is now measured in decades to coincide with improvements in therapy.

High Response Rate, MRD Negativity Confirmed for Venetoclax in CLL

September 22nd 2017

Treatment with the BCL-2 inhibitor venetoclax (Venclexta) led to negative minimal residual disease (MRD) status in 40% of evaluable patients with relapsed/refractory chronic lymphocytic leukemia.

Dramatic Improvement in NHL Outcomes With CAR T-Cell Versus Standard Therapy

September 20th 2017

Treatment with the autologous anti-CD19 CAR T-cell therapy axicabtagene ciloleucel significantly improved outcomes in refractory non-Hodgkin lymphoma compared with standard therapies.

CAR T-Cell Therapy Active in High-Risk, Refractory CLL

September 20th 2017

Patients with refractory chronic lymphocytic leukemia achieved a high-response rate with CD19-targeted CAR T-cell therapy JCAR014.

Venetoclax Combination Improves PFS in Phase III CLL Trial

September 19th 2017

The combination of venetoclax and rituximab significantly improved progression-free survival compared with rituximab plus bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia (CLL),

FDA Approves Copanlisib for Follicular Lymphoma

September 14th 2017

The FDA has granted an accelerated approval to copanlisib (Aliqopa) as a treatment for patients with relapsed follicular lymphoma who have received at least 2 least prior systemic therapies.

FDA Grants Frontline Obinutuzumab Priority Review for Follicular Lymphoma

August 28th 2017

The FDA has granted a priority review to a supplemental biologics license application for obinutuzumab (Gazyva) in combination with chemotherapy, followed by obinutuzumab alone, for the first-line treatment of patients with follicular lymphoma.

Dr. Nastoupil on Efficacy With Pembrolizumab and Rituximab in Follicular Lymphoma

August 28th 2017

Loretta J. Nastoupil, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses efficacy findings of a study investigating the combination of pembrolizumab (Keytruda) and rituximab (Rituxan) in patients with relapsed follicular lymphoma.

Dr. Andorsky on Next Steps Following MAGNIFY Trial in Follicular Lymphoma

August 24th 2017

David J. Andorsky, MD, medical oncology/hematology, Rocky Mountain Cancer Centers, discusses the next steps of the phase IIIb randomized MAGNIFY study of lenalidomide (Revlimid) plus rituximab (Rituxan) followed by maintenance therapy in relapsed/refractory non-Hodgkin lymphoma, focusing on a cohort of patients with follicular lymphoma.